Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novocure Ltd Ord Sh
(NQ:
NVCR
)
18.02
+1.03 (+6.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novocure Ltd Ord Sh
< Previous
1
2
3
4
5
6
7
Next >
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
March 01, 2023
From
Novocure
Via
Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
March 01, 2023
From
Novocure
Via
Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
February 23, 2023
From
Novocure
Via
Business Wire
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
February 23, 2023
From
Novocure
Via
Business Wire
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
February 15, 2023
From
Novocure
Via
Business Wire
Novocure Announces Organizational Changes to Prepare for Future Growth
January 19, 2023
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
January 09, 2023
From
Novocure
Via
Business Wire
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Novocure
Via
Business Wire
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
Novocure
Via
Business Wire
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
November 29, 2022
From
Novocure
Via
Business Wire
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
November 23, 2022
From
Novocure
Via
Business Wire
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
November 17, 2022
From
Novocure
Via
Business Wire
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
November 15, 2022
From
Novocure
Via
Business Wire
Novocure Secures CE Mark for New Array
November 11, 2022
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2022 Financial Results
October 27, 2022
From
Novocure
Via
Business Wire
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
October 21, 2022
From
Novocure
Via
Business Wire
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
October 20, 2022
From
Novocure
Via
Business Wire
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
October 20, 2022
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2022 Financial Results
October 03, 2022
From
Novocure
Via
Business Wire
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
September 21, 2022
From
Novocure
Via
Business Wire
Novocure to Participate in Upcoming Investor Conferences
August 31, 2022
From
Novocure
Via
Business Wire
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
August 10, 2022
From
Novocure
Via
Business Wire
Novocure Reports Second Quarter 2022 Financial Results
July 28, 2022
From
Novocure
Via
Business Wire
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
July 27, 2022
From
Novocure
Via
Business Wire
Novocure to Report Second Quarter 2022 Financial Results
July 01, 2022
From
Novocure
Via
Business Wire
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
June 21, 2022
From
Novocure
Via
Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
June 03, 2022
From
Novocure
Via
Business Wire
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
May 26, 2022
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2022 Financial Results
April 28, 2022
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.